Tipiracil

• Description:

  Tipiracil is a thymidine phosphorylase (TPase) inhibitor.

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H320

• Target:

  Nucleoside Antimetabolite/Analog; Thymidylate Synthase

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Tipiracil.html

• Purity:

  99.98

• Solubility:

  DMSO : < 1 mg/mL (ultrasonic; warming) |H2O : 1 mg/mL (ultrasonic)

• Smiles:

  O=C1NC(C(Cl)=C(CN2C(CCC2)=N)N1)=O

• Molecular Formula:

  C9H11ClN4O2

• Molecular Weight:

  242.66

• Precautions:

  H315, H319, H320

• References & Citations:

  [1]Lee SJ, et al. Thymidine phosphorylase influences [ (18) F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2014 Jul;41 (7) :1327-35.|[2]Raedler LA. Lonsurf (Trifluridine plus Tipiracil) : A New Oral Treatment Approved for Patients with Metastatic Colorectal Cancer. Am Health Drug Benefits. 2016 Mar;9 (Spec Feature) :97-100.|[3]Tanaka N, et al. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol Rep. 2014 Dec;32 (6) :2319-26.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Citation 01:

  Oncol Rep. 2023 Mar;49 (3) :52.|Biomed Pharmacother. 2021 Jul:139:111672.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|Mod Rheumatol. 2018 May;28 (3) :495-505.|Patent. US Patent 11110111.

• CAS Number:

  [183204-74-2]